Belimumab in the treatment of systemic lupus erythematous: An evidence based review of its place in therapy

被引:21
作者
Marcondes, Frederico [1 ]
Scheinberg, Morton [2 ]
机构
[1] Univ Fed Rio de Janeiro, Rio De Janeiro, Brazil
[2] Hosp Israelite Albert Einstein, Sao Paulo, Brazil
关键词
Systemic lupus erythematosus; Belimumab; Autoimmune disease; REAL-LIFE EXPERIENCE; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; DISEASE-ACTIVITY; SLE; EFFICACY; SAFETY; BLISIBIMOD; INHIBITOR; NEPHRITIS; RITUXIMAB;
D O I
10.1016/j.autrev.2017.11.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Systemic lupus erythematous is an autoimmune disease with diverse clinical features and has its development associated with a complexity of genetic, hormonal and environmental factors and the development of autoantibodies. Identification of new treatments is currently an area of intense investigation. Belimumab is the first biologic approved for the treatment of the disease inhibiting the excessive B cell activity observed in these patients and consequently reduction of autoantibodies. Aim: To review the current transition of the evidence available of its use in real life patients with persistent active disease while on conventional therapies. Evidence: The results observed on the large series of patients (over 50 patients) followed for at least six months confirm the observations from phase 3 trials. In clinical practice close to two third of the patients remained on belimumab and one third discontinued mostly due to evaluation by the doctor or the patient or both of no detectable positive response. The presence of adverse events was considerably low and the subgroups with skin and joint manifestations appear to benefit the most. Daily steroid use is usually reduced to a significantly low when compared with the intake before introduction of the biologic Although not seen on trials in real life the addition of belimumab to the conventional therapy in lupus nephritis is being reported in several patients. Cost of the medication is still an issue that hampers its use. Further evidence of its use in certain specific groups is under investigation and its results should shed light on additional indications. Place in therapy: Considering what is currently published on the evidence here reviewed in the use of belimumab in clinical practice it is our understanding that belimumab it will be gradually incorporated in the armamentarium of treatment not necessarily on refractory patients. We believe that with the upcoming of the subcutaneous route in the near future should also help in widen the use of the belimumab to be considered in first line combination set ups. (C) 2017 Published by Elsevier B.V.
引用
收藏
页码:103 / 107
页数:5
相关论文
共 49 条
[1]  
Andreoli L, 2014, ISR MED ASSOC J, V16, P651
[2]  
[Anonymous], 2008, DRUGS R&D, V9, P197
[3]   Belimumab in systemic lupus erythematosus (SLE): evidence-to-date and clinical usefulness [J].
Castro, Sara Guerreiro ;
Isenberg, David A. .
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2017, 9 (03) :75-85
[4]  
Chatham W, 2017, LUPUS, V1
[5]   Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA [J].
Collins, C. E. ;
Dall'Era, M. ;
Kan, H. ;
Macahilig, C. ;
Molta, C. ;
Koscielny, V. ;
Chang, D. J. .
LUPUS SCIENCE & MEDICINE, 2016, 3 (01)
[6]   Use of belimumab throughout pregnancy to treat active systemic lupus erythematosus-A case report [J].
Danve, Abhijeet ;
Perry, Lisa ;
Deodhar, Atul .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (02) :195-197
[7]   Case report: successful treatment of membranous lupus nephritis with belimumab in an African female immigrant [J].
De Scheerder, Marie-Angelique ;
Boey, O. ;
Mahieu, E. ;
Vanuytsel, J. ;
Bogaert, Anne-Marie .
CLINICAL RHEUMATOLOGY, 2016, 35 (06) :1649-1653
[8]   SAFETY OF SUBCUTANEOUS BELIMUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 6-MONTH OPEN-LABEL EXTENSION STUDY [J].
Doria, A. ;
Stohl, W. ;
Schwarting, A. ;
Scheinberg, M. ;
Hammer, A. ;
Kleoudis, C. ;
Groark, J. ;
Fox, N. L. ;
Roth, D. ;
Bass, D. ;
Gordon, D. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 :861-861
[9]   REAL-LIFE EXPERIENCE WITH BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): CONTROL OF DISEASE ACTIVITY AND FLARES IN A MULTICENTER COHORT [J].
Fanouriakis, A. ;
Adamichou, C. ;
Koulsoviti, S. ;
Klagou, A. ;
Tsalapaki, C. ;
Konsta, S. ;
Dimopoulou, D. ;
Ntali, S. ;
Vassilopoulos, D. ;
Konstantopoulou, P. ;
Elezoglou, A. ;
Sidiropoulos, P. ;
Erden, A. ;
Bertsias, G. ;
Boumpas, D. .
ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 :1204-1205
[10]   Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman [J].
Fliesser, E. E. ;
Korsten, P. ;
Koziolek, M. J. ;
Niewold, T. B. ;
Patschan, D. ;
Mueller, G. A. ;
Patschan, S. A. .
LUPUS, 2013, 22 (14) :1523-1525